ISPOR Europe 2025 Home
  • About
    • Registration Information
    • News Center
  • Program
    • Program
    • Plenary Sessions
    • Posters
    • Student Program
    • Learning Formats
    • Program Committee
    • Digital Conference Pass
  • Exhibits & Sponsorship
    • Sponsors
    • Media Partners
    • Exhibitor Directory
  • Photo Gallery
  • Award Winners
large-circle

ISPOR Europe 2025

9 - 12 November

  • Home
  • Events
  • Past Conferences
  • ISPOR Europe 2025
  • Program
  • Program
  • Session
  • Beyond P-Values and Sample Size Calculations: Probability of Success for Indirect Comparative Efficacy Forecasting and Its Role in Industry Decision Making

    Sep 22, 2025, 16:24
  • Adding Nature’s Petal to the Value Flower: Can Inclusion of Environmental Impact in HTA Aid the Race to Net Zero?

    Sep 22, 2025, 16:24
  • A New Era for EU HTA: What Can the EU HTAR Learn From the EMA’s Path to Harmonization?

    Sep 22, 2025, 16:24
  • Increasing Transparency of Public Funding in Pharmaceutical Research and Development Reporting

    Sep 22, 2025, 16:24
  • How Can We Make Innovative Payment And Pricing Schemes a "Win" From All Perspectives?

    Sep 22, 2025, 16:24
  • Optimal Strategies for Predicting and Consolidating PICOs: One Best Method or a Blended Approach?

    Sep 22, 2025, 16:24
  • A Match Made in Heaven? Optimal Selection of Preference Elicitation Methods to Address Study Purpose and Objectives

    Sep 22, 2025, 16:24
  • Final Recommendations From the ISPOR Taskforce on Statistical Evaluation of Surrogacy Endpoints for Value Demonstration and Health Economic Modeling

    Sep 22, 2025, 16:24
  • Harmonizing and Enabling Cross-Border Real-World Evidence Studies in Europe

    Sep 22, 2025, 16:24
  • Vaccine Value Assessment in CEE Countries: Challenges and Opportunities

    Sep 22, 2025, 16:24
  • Defining Appropriate Benefits for Economic Evaluation: Do Recommendations From HEMA Help?

    Sep 22, 2025, 16:24
  • HEOR Impact Cases in Oncology and Rare Disease

    Sep 22, 2025, 16:24
  • Integrating Environmental, Well-Being, and Public Health in Health Economic Assessment

    Sep 22, 2025, 16:24
  • Gen AI in Systematic Literature Reviews: First Case Study on Gen AI in a NICE Submission

    Sep 22, 2025, 16:24
  • Making Health Equity Actionable in HTA: From Frameworks to Implementation

    Sep 22, 2025, 16:24
  • Maximizing Patients' Voices in HTA: Innovations in Elicitation Practices

    Sep 22, 2025, 16:24
  • What Lessons Can the US Learn from Europe’s Experience With International Reference Pricing?

    Sep 22, 2025, 16:24
  • Expanding the Evidence Base in Network Meta-Analysis: Leveraging Surrogacy Meta-Analysis and Matching Techniques

    Sep 22, 2025, 16:24
  • Can We Quantify the Public Health Impact of Vaccines in Mitigating Antimicrobial Resistance?

    Sep 22, 2025, 16:24
  • Trusting a Machine? Opportunities and Challenges to Using Artificial Intelligence in Qualitative Patient Research

    Sep 22, 2025, 16:24
  • 1
  • 2
  • 3
  • 4
  • 5 (current)
  • 6
  • 7
  • 8
  • 9
  • 10
Quick Links

  • About ISPOR
  • Media Center
  • Exhibits & Sponsorships
  • Contact Us
Policies & Legal

  • Antitrust Compliance
  • Code of Ethics
  • Diversity Policy
  • Funding Statement
  • Legal Disclaimer
  • Privacy Policy

Subscribe

Join ISPOR


ISPOR–The Professional Society for
Health Economics and Outcomes Research

Copyright © 2018 ISPOR. All rights reserved.

International Society for Pharmacoeconomics and Outcomes Research, Inc

Website Design & Development by Matrix Group